Consistent with preclinical observations, they extended these findings in a cohort of 233 cetuximab-treated CRC patients, demonstrating a shorter PFS and OS in those patients with HER2-amplified tumors and higher serum heregulin levels. The gene discussed is ERBB2; the disease is colorectal carcinoma.